| Treating Diabetes and Understanding Cultures http://online.wsj.com/artic... Diabetes Articles Wall Street Journal - With minorities now accounting for nearly a third of the U.S. population, medical professionals are beginning to bone up on so-called cultural competency, part of a broad effort to ensure that patients from disparate backgrounds all get proper care ... |
| Pfizer's Profit Plunges on Write-Off of Diabetes Drug (Update2) http://www.bloomberg.com/ap... Diabetes Articles Bloomberg - Oct. 18 (Bloomberg) -- Pfizer Inc., the world's largest drugmaker, said third-quarter profit fell 77 percent on costs for discontinuing the diabetes treatment Exubera and on competition from cheaper copies of its best-selling drugs. Pfizer abandoned ... |
| Critics say ads on obesity lack punch http://www.boston.com/news/... Diabetes Articles Boston Globe - That drama is lacking in the obesity spots - for example, none have offered a surgeon's view of fat, or dramatized a death from Type 2 diabetes, or shown a person complaining about how a fat neighbor's medical bills are costing taxpayers. In the past ... |
| 5 things you didn't know about the flu http://www.miamiherald.com/... Diabetes Articles Miami Herald - ... Who's most at risk? The government recommends a flu shot for kids aged 6 months to 5 years, pregnant women, people 50 and older or living in nursing homes and those with chronic conditions such as congestive heart failure, asthma or diabetes. 5 Cover ... |
| Pfizer's Exubera Flop http://www.businessweek.com... Diabetes Articles BusinessWeek - Exubera was supposed to revolutionize diabetes care. It was the first inhalable insulin product on the market, invented by biotech startup Nektar Therapeutics ( NKTR ) and shepherded to market by drug giant Pfizer ( PFE ), which predicted it would ... |
| Pfizer tumbles on diabetes drug flop http://www.ft.com/cms/s/6e2... Diabetes Articles Financial Times - Pfizer , the world’s largest drugmaker, said third quarter net income fell 77 per cent because of a $2.8bn charge from abandoning Exubera, its diabetes drug, and increased competition from generic medicines. Net earnings were $761m, down from $3 ... |
| Pfizer 3Q Profit Falls on Exubera Charge http://www.forbes.com/feeds... Diabetes Articles Forbes - Sales of diabetes drug Exubera have been disappointing for both the company and Wall Street since its launch. The company said it will return licensing rights to partner Nektar Therapeutics (nasdaq: NKTR - news - people ) Inc. and ... |
| Aspreva, Husky, Moly Mines, Prizm, QLT: Canada Equity Preview http://www.bloomberg.com/ap... Diabetes Articles Bloomberg - The drugmaker said in a CNW statement that final results of Phase I/II multiple-dose trials of Exendin-4 show that the treatment for Type 2 diabetes was ``well tolerated'' and ``effective in lowering blood glucose'' if taken in the tested dosages ... |
| Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting ... http://news.moneycentral.ms... Diabetes Articles MSN MoneyCentral - CARLSBAD, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. ISIS today announced that it has added a new diabetes drug targeting the sodium dependent glucose transporter type 2 (SGLT2) to its development pipeline. ISIS 388626, a ... |
| Paint-A-Pumpkin fundraiser aims to fight juvenile diabetes http://www.newstimes.com/ci... Diabetes Articles Danbury News-Times - Madison Halas, 6, who has juvenile diabetes, selects one of the pumpkins that will be sold as part of Halas Farm Market’s third annual Paint-A-Pumpkin fundraiser Sunday, with proceeds benefiting the Juvenile Diabetes Research Foundation. The ... |